Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Long-Term Investments (2022 - 2025)

Harmony Biosciences Holdings' Long-Term Investments history spans 4 years, with the latest figure at $107.1 million for Q4 2025.

  • For Q4 2025, Long-Term Investments fell 1.6% year-over-year to $107.1 million; the TTM value through Dec 2025 reached $107.1 million, down 1.6%, while the annual FY2025 figure was $107.1 million, 1.6% down from the prior year.
  • Long-Term Investments for Q4 2025 was $107.1 million at Harmony Biosciences Holdings, up from $105.8 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $108.9 million in Q4 2024 and bottomed at $4.7 million in Q2 2022.
  • The 4-year median for Long-Term Investments is $81.2 million (2024), against an average of $71.8 million.
  • The largest annual shift saw Long-Term Investments soared 1135.54% in 2023 before it fell 1.6% in 2025.
  • A 4-year view of Long-Term Investments shows it stood at $22.6 million in 2022, then soared by 219.78% to $72.2 million in 2023, then surged by 50.86% to $108.9 million in 2024, then fell by 1.6% to $107.1 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Long-Term Investments are $107.1 million (Q4 2025), $105.8 million (Q3 2025), and $107.0 million (Q2 2025).